Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
Due to groundbreaking developments and continuous progress, the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting, but increasingly challenging task. This applies, in particular, to the subgroup of NSCLC with oncogenic driver alterations. While the treatm...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/804 |
| _version_ | 1797396520678457344 |
|---|---|
| author | David König Spasenija Savic Prince Sacha I. Rothschild |
| author_facet | David König Spasenija Savic Prince Sacha I. Rothschild |
| author_sort | David König |
| collection | DOAJ |
| description | Due to groundbreaking developments and continuous progress, the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting, but increasingly challenging task. This applies, in particular, to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged NSCLC with various tyrosine kinase inhibitors (TKIs) is well-established, new targets have been identified in the last few years and new TKIs introduced in clinical practice. Even for KRAS mutations, considered for a long time as an “un-targetable” alteration, promising new drugs are emerging. The detection and in-depth molecular analysis of resistance mechanisms has further fueled the development of new therapeutic strategies. The objective of this review is to give a comprehensive overview on the current landscape of targetable oncogenic alterations in NSCLC. |
| first_indexed | 2024-03-09T00:52:34Z |
| format | Article |
| id | doaj.art-6622558cc4ff4305a966b78784d11f7f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T00:52:34Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6622558cc4ff4305a966b78784d11f7f2023-12-11T17:07:21ZengMDPI AGCancers2072-66942021-02-0113480410.3390/cancers13040804Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver AlterationsDavid König0Spasenija Savic Prince1Sacha I. Rothschild2Department of Medical Oncology, University Hospital Basel, 4031 Basel, SwitzerlandComprehensive Cancer Center, University Hospital Basel, 4031 Basel, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, 4031 Basel, SwitzerlandDue to groundbreaking developments and continuous progress, the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting, but increasingly challenging task. This applies, in particular, to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged NSCLC with various tyrosine kinase inhibitors (TKIs) is well-established, new targets have been identified in the last few years and new TKIs introduced in clinical practice. Even for KRAS mutations, considered for a long time as an “un-targetable” alteration, promising new drugs are emerging. The detection and in-depth molecular analysis of resistance mechanisms has further fueled the development of new therapeutic strategies. The objective of this review is to give a comprehensive overview on the current landscape of targetable oncogenic alterations in NSCLC.https://www.mdpi.com/2072-6694/13/4/804NSCLConcogenic alterationstargeted therapyKRAS mutationsKRAS G12C inhibitorsEGFR mutation |
| spellingShingle | David König Spasenija Savic Prince Sacha I. Rothschild Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations Cancers NSCLC oncogenic alterations targeted therapy KRAS mutations KRAS G12C inhibitors EGFR mutation |
| title | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations |
| title_full | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations |
| title_fullStr | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations |
| title_full_unstemmed | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations |
| title_short | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations |
| title_sort | targeted therapy in advanced and metastatic non small cell lung cancer an update on treatment of the most important actionable oncogenic driver alterations |
| topic | NSCLC oncogenic alterations targeted therapy KRAS mutations KRAS G12C inhibitors EGFR mutation |
| url | https://www.mdpi.com/2072-6694/13/4/804 |
| work_keys_str_mv | AT davidkonig targetedtherapyinadvancedandmetastaticnonsmallcelllungcanceranupdateontreatmentofthemostimportantactionableoncogenicdriveralterations AT spasenijasavicprince targetedtherapyinadvancedandmetastaticnonsmallcelllungcanceranupdateontreatmentofthemostimportantactionableoncogenicdriveralterations AT sachairothschild targetedtherapyinadvancedandmetastaticnonsmallcelllungcanceranupdateontreatmentofthemostimportantactionableoncogenicdriveralterations |